Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.

Gingelmaier A, Kurowski M, Kästner R, Eberle J, Mylonas I, Belohradsky BH, Friese K, Grubert TA.

AIDS. 2006 Aug 22;20(13):1737-43.

PMID:
16931938
2.

Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M.

Ther Drug Monit. 2008 Oct;30(5):604-10. doi: 10.1097/FTD.0b013e3181867a6e.

PMID:
18728627
3.

Transplacental passage of protease inhibitors at delivery.

Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T; Swiss Mother + Child HIV Cohort Study.

AIDS. 2002 Apr 12;16(6):889-93.

PMID:
11919490
4.
5.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
6.

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

Chappuy H, Tréluyer JM, Rey E, Dimet J, Fouché M, Firtion G, Pons G, Mandelbrot L.

Am J Obstet Gynecol. 2004 Aug;191(2):558-62.

PMID:
15343237
7.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
8.

Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

Ivanovic J, Nicastri E, Anceschi MM, Ascenzi P, Signore F, Pisani G, Vallone C, Mattia E, Notari S, Tempestilli M, Pucillo LP, Narciso P; Pregnancy And Newborn Clinical Outcome Group in HIV Infection (PANCOH).

Curr HIV Res. 2009 Nov;7(6):620-5.

PMID:
19929798
9.

Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F.

Br J Clin Pharmacol. 2008 Aug;66(2):179-95. doi: 10.1111/j.1365-2125.2008.03220.x. Epub 2008 May 15. Review.

10.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
11.

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi L.

HIV Med. 2006 Jul;7(5):338-44.

12.

Concentrations of protease inhibitors in cord blood after in utero exposure.

Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL.

Pediatr Infect Dis J. 2002 Sep;21(9):835-8.

PMID:
12352805
13.

Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, Rouet F, Becquet R, Leroy V, El-Sadr WM, Abrams EJ, Dabis F.

PLoS Med. 2007 Aug;4(8):e257.

14.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
15.

The value of highly active antiretroviral therapy in the prevention of mother-to-child transmission of HIV.

Chama C, Gashau W, Oguche S.

J Obstet Gynaecol. 2007 Feb;27(2):134-7.

PMID:
17454457
16.

Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.

McCormack SA, Best BM.

Clin Pharmacokinet. 2014 Nov;53(11):989-1004. doi: 10.1007/s40262-014-0185-7. Review.

17.

Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.

Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, Capparelli E, Mirochnick M.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):283-8.

PMID:
15735445
18.

Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.

Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L; ANRS French Perinatal Cohort.

AIDS. 2008 Jan 11;22(2):289-99.

PMID:
18097232
19.

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F; Ghent Group on HIV in Women and Children.

Int J Epidemiol. 2007 Oct;36(5):1009-21. Epub 2007 May 28. Review.

PMID:
17533166
20.

Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.

Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L.

AIDS. 2006 Jan 9;20(2):217-22.

PMID:
16511414

Supplemental Content

Support Center